OBJECTIVE: To identify prognostic survival factors among Mexican women with cervical cancer. METHODS: A total of 378 women with cervical cancer admitted from 1984 to 1996 to our referral hospital were evaluated, using survival analysis (Kaplan-Meier and Cox proportional hazards method). We designed a symptom index which included asymptomatic conditions, severity of symptoms and comorbidity. RESULTS: Overall 5-year survival was 66.6%. The shortest survival time was for FIGO stage IV (21.5%, P<0.001) and adenosquamous histologic type (53.1%, P=0.15). The main prognostic factors were primary symptoms (RR, 2.6; 95% CI, 1.02-6.66); systemic symptoms (RR, 3.3; 95% CI, 1.23-9.01); FIGO stage IV (RR, 5.5; 95% CI, 2.36-12.96); and oncogenic symptoms (prognostic comorbidity present) (RR, 2.3; 95% CI, 1.08-4.89). CONCLUSIONS: Our findings show that clinical stage and several types of symptoms influence CC survival. This present strategy to assess morphological and clinical characteristics may be a more accurate indicator of survival rate and potentially an efficient indicator of new therapeutic alternatives.
OBJECTIVE: To identify prognostic survival factors among Mexican women with cervical cancer. METHODS: A total of 378 women with cervical cancer admitted from 1984 to 1996 to our referral hospital were evaluated, using survival analysis (Kaplan-Meier and Cox proportional hazards method). We designed a symptom index which included asymptomatic conditions, severity of symptoms and comorbidity. RESULTS: Overall 5-year survival was 66.6%. The shortest survival time was for FIGO stage IV (21.5%, P<0.001) and adenosquamous histologic type (53.1%, P=0.15). The main prognostic factors were primary symptoms (RR, 2.6; 95% CI, 1.02-6.66); systemic symptoms (RR, 3.3; 95% CI, 1.23-9.01); FIGO stage IV (RR, 5.5; 95% CI, 2.36-12.96); and oncogenic symptoms (prognostic comorbidity present) (RR, 2.3; 95% CI, 1.08-4.89). CONCLUSIONS: Our findings show that clinical stage and several types of symptoms influence CC survival. This present strategy to assess morphological and clinical characteristics may be a more accurate indicator of survival rate and potentially an efficient indicator of new therapeutic alternatives.
Authors: Dan Wu; Yuhuan Qiao; Gunnar B Kristensen; Shanshan Li; Gunhild Troen; Ruth Holm; Jahn M Nesland; Zhenhe Suo Journal: Pathol Oncol Res Date: 2004-12-27 Impact factor: 3.201